HORMONE IN PROSTATIC FLUID AND PROSTATE CANCER RISK

目的是进行可行性和探索性研究， 美国黑人和白色人前列腺癌的生化流行病学 在纽约市，将在血清和 前列腺液 将对病例和对照进行访谈， 收集已知和疑似前列腺癌风险因素的数据。 的 两个对照组，频率匹配的医院，种族和年龄，将 包括无全身恶性肿瘤既往史的患者 泌尿外科以外的外科服务， 确诊为良性前列腺增生 雌二醇，雌酮， 睾酮、双氢睾酮和催乳素将通过以下方法测定： 放射免疫法 此外，将通过大鼠Nb2测定催乳素 淋巴瘤细胞生物测定，研究的分子形式，并进行比较 催乳素的生物测定和放射免疫测定水平， 病例和对照。 前列腺液激素测定结果将有助于 与血清中的那些相关，与已知的和怀疑的 不同病例对照亚组的流行病学危险因素。 目的是确定一种新的方法来研究前列腺内分泌学 并最终将其应用于深入的国际调查 在不同种族的黑人和白色人群中， 前列腺癌的风险水平。

The objective is to perform a feasibility and exploratory study of the biochemical epidemiology of prostate cancer in black and white patients in New York City in which selected hormones will be assayed in both serum and prostatic fluid. Interviews will be conducted with cases and controls to collect data on known and suspected risk factors for prostate cancer. The two control groups, frequency-matched by hospital, race and age, will consist of patients without prior history of malignancy from general surgical services other than urology, and patients with histologically confirmed benign prostatic hyperplasia. Levels of estradiol, estrone, testosterone, dihydrotestosterone and prolactin will be determined by radioimmunoassay. In addition, prolactin will be measured by the rat Nb2 lymphoma cell bioassay, the molecular forms studied, and comparisons made of the bioassayable and radioimmunoassayable levels of prolactin in both cases and controls. The results of hormone assays of prostatic fluid will be correlated with those of serum, and with known and suspected epidemiological risk factors in the various case-control subgroups. The goal is to define a new approach to the study of prostate endocrinology and, ultimately, to apply this to an in-depth international investigation of biochemical epidemiology in black and white populations of differing levels of prostate cancer risk.